Cardio Diagnostics Holdings, Inc. (CDIO)
NASDAQ: CDIO · Real-Time Price · USD
0.4840
-0.0359 (-6.91%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.

It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.

It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations.

Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Meeshanthini Dogan

Contact Details

Address:
311 West Superior Street, Suite 444
Chicago, Illinois 60654
United States
Phone 855 226 9991
Website cdio.ai

Stock Details

Ticker Symbol CDIO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001870144
CUSIP Number 14159C103
ISIN Number US14159C1036
Employer ID 87-0925574
SIC Code 2835

Key Executives

Name Position
Dr. Meeshanthini V. Dogan Ph.D. Co-Founder, Chief Executive Officer and Director
Elisa Michael Luqman Esq., J.D., M.B.A. Chief Financial Officer and Principal Accounting Officer
Timur Dogan Ph.D. Chief Technology Officer
Dr. Robert A. Philibert M.D., Ph.D. Co-Founder, Chief Medical Officer and Director
Khullani Abdullahi J.D. Vice President of Revenue and Strategy

Latest SEC Filings

Date Type Title
Apr 8, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 25, 2025 424B3 Prospectus
Mar 25, 2025 424B3 Prospectus
Mar 20, 2025 10-K Annual Report
Feb 21, 2025 8-K Current Report
Feb 14, 2025 EFFECT Notice of Effectiveness
Feb 14, 2025 424B5 Filing
Feb 13, 2025 UPLOAD Filing
Feb 7, 2025 S-3 Registration statement under Securities Act of 1933
Dec 4, 2024 8-K Current Report